Document:

Confidential Settlement and License Agreement

 Exhibit 10.22 
 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
 CONFIDENTIAL SETTLEMENT & LICENSE AGREEMENT 
 This CONFIDENTIAL SETTLEMENT & LICENSE AGREEMENT (“Agreement”) is entered into and made effective as of October 16, 2009 (“Effective Date”) by and between SonoSite, Inc., a
Washington corporation, and General Electric Company, a New York corporation. 
 1. BACKGROUND 
 1.1 GE and SonoSite each manufacture and sell ultrasound products. 
 1.2 GE and SonoSite each own patents and patent applications in the area of ultrasound technology. 
 1.3 GE and SonoSite are engaged in several pending patent disputes and desire to resolve those disputes as well as to accomplish certain additional, mutually desirable business objectives. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good consideration, the sufficiency of which is
hereby acknowledged, the parties hereto agree as follows: 
 2. DEFINITIONS 
 2.1 “Actions” means, collectively, (a) the parties’ lawsuit in the federal district court for the Western District of
Wisconsin, Case No. 08-cv-298-bbc, (b) the parties’ Federal Circuit appeal of the lawsuit from the Western District of Wisconsin, Case No. 07-C-0273-C, as well as all claims and counterclaims in the underlying case, and
(c) the parties’ nullity action in the German Federal Patents Court, Case No. 4 Ni 33/09 (EU). 
 2.2
“Affiliate” of a party hereto means any corporation, limited liability company, partnership, joint venture or other legal person or entity of any kind that now or in the future is directly or indirectly controlled by, or is
under common control with, such party, but only so long as such control exists. For purposes of this definition, “control” or “controlled” shall mean, with respect to: (a) a corporation, the direct or indirect ownership of a
majority of the stock entitled to vote upon election of directors or persons performing similar functions, or direct or indirect ownership of the maximum percentage of such stock permitted under local laws or regulations in those countries where
majority ownership by a foreign entity is not permitted, and (b) any other entity, the affirmative power to direct or cause the direction of the management and policies of such entity (whether through ownership of securities, partnership or
membership interests, by contract, by membership in the board of directors, management committee or other management structure of such entity, or otherwise). 
  

 - 1 - 

 2.3 “Average Sales Price” means, for a Royalty-Based Product, the average Net Sales
amount for such Royalty-Based Product during the [**] quarter [**] during which such Royalty-Based Product is Sold. In calculating the Average Sales Price [**] shall not be included when calculating the Average Sales Price of such Royalty-Based
Product in [**]. For the [**] of Sales of a Royalty-Based Product, Average Sales Price shall mean the average of [**] of the Net Sales amounts for that Royalty-Based Product in [**]; provided that Royalty-Based Products that are Sold by or on behalf
of GE in [**] for no cash consideration shall be excluded [**] is determined. 
 2.4 “Change of Control” of an
entity means the occurrence of any of the following events: 
 (a) a transaction or series of transactions whereby any
“person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the
Exchange Act) of securities of the entity possessing greater than fifty percent (50%) of the total combined voting power of the entity’s securities outstanding immediately after such acquisition; or 
 (b) the consummation by the entity of (i) a merger, consolidation, reorganization or business combination or (ii) a sale or other
disposition of all or substantially all of the entity’s assets related to medical ultrasound, in each case, other than a transaction in which the holders of the equity interests in the entity immediately prior to the transaction will,
immediately after such transaction, have greater than fifty percent (50%) of the voting power of the equity interests in the entity that survives the merger, consolidation, reorganization or business combination or acquire all or substantially
all of the entity’s assets related to medical ultrasound or otherwise succeed to the business of the entity, which voting securities are to be held by such holders immediately following such transaction in substantially the same proportion
among themselves as such holders’ ownership of the equity interests in the entity immediately before such transaction. 
 2.5
“Claim” or “Claims” means any and all claims, counterclaims, cross-claims, defenses, affirmative defenses, causes of action of any type (whether common law, statutory, regulatory or
administrative, and whether reduced to judgment, liquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured or unsecured), demands, disputes, damages, costs, losses, detriments, interest, expenses, penalties,
attorneys’ fees, actions, controversies, suits and civil actions, whether known or unknown, as against each other, relating to, arising out of, or in any way concerning the Actions. 
 2.6 [**] means, in a given [**], a Royalty-Based Product with a Net Sales [**] (as determined for the [**]) for such Royalty-Based Product. 
  
  

	**	Confidential Treatment Requested. 

  

 - 2 - 

 2.7 “GE” means General Electric Company, a New York corporation, and its current and
future Affiliates, directors, officers, employees, divisions, representatives and agents, including, without limitation, distributors and wholesalers. 
 2.8 “Licensed GE Patents” means U.S. Patent Nos. 4,932,415, 5,584,294, 6,102,859, 6,120,447, 6,210,327 and 6,418,225, and their corresponding Patent Families. 
 2.9 “Licensed GE Products” means current and future GE ultrasound products and any associated components, accessories and/or
services that, absent the license granted to GE hereunder, would infringe one or more of the Licensed SonoSite Patents. 
 2.10
“Licensed SonoSite Patents” means U.S. Patent Nos. 5,722,412, 5,817,024, 6,364,839, 6,471,651, 6,569,101 and 6,962,566, and their corresponding Patent Families. For the avoidance of doubt, all of the patents and applications
claiming priority to U.S. App. No. 08/672,782 (filed on June 28, 1996) are included in this definition. 
 2.11 “Licensed
SonoSite Products” means current and future SonoSite ultrasound products and any associated components, accessories and/or services that, absent the license granted to SonoSite hereunder, would infringe one or more of the Licensed GE
Patents. 
 2.12 “Net Sales” means, with respect to each Royalty-Based Product, [**]. All such deductions shall be
determined under Generally Accepted Accounting Principles in the United States, consistently applied. Any invoice payments received in currencies other than U.S. Dollars shall be converted into U.S. Dollars using the same method the General Electric
Company uses for its own financial accounting purposes. 
 2.13 “Patent Family” of a patent or patent application
referenced herein means: (a) the earliest patent application, anywhere in the world, to which the referenced patent or patent application claims priority; (b) all patent applications, anywhere in the world, that now or in the future
directly or indirectly claim priority to the patent application identified in (a) above; and (c) all patent rights of any type granted at any time anywhere in the world on any of the patent applications identified in (a) or
(b) above. For the avoidance of doubt, (b) above includes, without limitation, all continuation, continuation-in-part, divisional or foreign counterpart applications that directly or indirectly claim priority to the patent application
identified in (a) above. 
 2.14 “Royalty-Based Product” means a current or future Licensed GE Product that
consists of [**]. Any dispute concerning what should or should not be included for purposes of determining the relevant weight of such ultrasound system shall be resolved pursuant to Section 6.2 hereof and shall be in accordance with the
Opinion and Order of May 26, 2009, issued by the United States District Court for the Western District of Wisconsin. 
  
  

	**	Confidential Treatment Requested. 

  

 - 3 - 

 2.15 “Royalty Period” means, unless terminated earlier pursuant to Section 11,
the period of time beginning on the Effective Date and continuing until the expiration of U.S. Patent No. 5,722,412. 
 2.16
“Sale” or “Sold” means any sale or transfer of title, whether by lease, donation, or otherwise. 
 2.17 “SonoSite” means SonoSite, Inc., a Washington corporation, and its current and future Affiliates, directors, officers, employees, divisions, representatives and agents, including, without limitation,
distributors and wholesalers. 
 2.18 “Territory” means the world. 
 2.19 “Third Party” means any person or entity other than GE or SonoSite. 
 3. LITIGATION DISMISSAL AND GENERAL RELEASES 
 3.1 Vacation of Rulings and Dismissal of Lawsuits. Either party may, within five (5) business days of the Effective Date, cause their counsel to
prepare and submit to the Western District of Wisconsin and to the Court of Appeals for the Federal Circuit documents necessary to request vacatur of the substantive rulings made by the Western District of Wisconsin in the Actions. The moving party
shall be permitted to represent that the non-moving party has no objection to said request. Within five (5) business days following the order(s) by the Western District of Wisconsin vacating or denying vacatur of its substantive rulings (or the
expiration of the initial five day period if neither party seeks vacatur), the parties shall cause their counsel to dismiss with prejudice, on the merits, without costs, fees or other award to either party, all of their Claims in the Actions. The
parties shall cause their counsel to cooperate in filing or lodging any additional documents required to obtain the vacation of substantive rulings and dismissal of the Actions with prejudice. 
 3.2 General Release by GE. In consideration of the promises and covenants herein contained and the licenses and releases granted by SonoSite to GE in
Section 4, GE does hereby remise, forgive, release and forever discharge SonoSite and its successors-in-interest and permitted assigns from any and all Claims, actions, causes of action, liabilities, obligations and demands, of any nature
whatsoever, arising prior to the Effective Date now known or which may hereafter become known, with respect to any of the matters referred to in the Actions or matters relating thereto, arising out of, or in any way concerning the Claims. It is the
intent of the parties and of this Agreement to give the broadest release and discharge of activities prior to the Effective Date possible under the law. 
 3.3 General Release by SonoSite. In consideration of the promises and covenants herein contained and the licenses and releases granted by GE to SonoSite in Section 4, SonoSite does hereby
remise, forgive, release and forever discharge GE and its successors-in-interest and permitted assigns from any and all Claims, actions, causes of action, liabilities, obligations and demands, of any nature whatsoever, arising prior to the Effective
Date now known or which may hereafter become known, with respect to any of the matters referred to in the Actions or matters

  

 - 4 - 

 
relating thereto, arising out of, or in any way concerning the Claims. It is the intent of the parties and of this Agreement to give the broadest release and discharge of activities prior to the
Effective Date possible under the law. 
 4. PATENT LICENSES & RELEASES 

4.1 GE Patents. Subject to GE’s termination rights under Section 11, GE grants to SonoSite, and direct and indirect customers of Licensed
SonoSite Products, a non-exclusive, non-transferable, fully paid-up, perpetual, worldwide license under the Licensed GE Patents, without the right to sublicense, to make, have made, use, offer to sell, sell, import, or otherwise dispose of Licensed
SonoSite Products in the Territory. GE releases SonoSite (as “SonoSite” is constituted as of the Effective Date), and direct and indirect customers of Licensed SonoSite Products, from any and all claims, demands, and rights of action for
any direct or indirect infringement of the Licensed GE Patents occurring before the Effective Date. 
 4.2 SonoSite Patents. Subject to
SonoSite’s termination right under Section 11, SonoSite grants to GE, and direct and indirect customers of Licensed GE Products, a non-exclusive, non-transferable, perpetual, worldwide license under the Licensed SonoSite Patents, without
the right to sublicense, to make, have made, use, offer to sell, sell, import, or otherwise dispose of Licensed GE Products in the Territory. SonoSite releases GE (as “GE” is constituted as of the Effective Date), and direct and indirect
customers of Licensed GE Products, from any and all claims, demands, and rights of action for any direct or indirect infringement of the Licensed SonoSite Patents occurring before the Effective Date. 
 4.3 No Implied Licenses. Other than as expressly stated herein, no licenses or other rights are granted or may be implied to SonoSite or GE under
this Agreement, whether by implication, inducement, estoppel or otherwise. 
 4.4 Patent Challenge. In consideration of the licenses and
releases granted by each party to the other party under Sections 3 and 4 and the other terms and conditions of this Agreement, during the term of this Agreement GE and SonoSite shall not challenge the validity or enforceability of any of the other
party’s patents for which a non-exclusive license has been granted to the licensee party hereunder, including, without limitation, in a reissue, re-examination, interference or opposition proceeding, and such licensee party shall not support or
assist any Third Party in challenging the validity or enforceability, or infringement of such licensor party’s patents, including, without limitation, in a reissue, re-examination, interference or opposition proceeding or through the use of
documents, information and/or other work product pertaining to such licensor party’s patents that such licensee party and/or its attorneys developed in connection with the Actions. This Section 4.4 shall not apply to a party hereto if,
during the term of this Agreement: (a) such party is accused of infringing one or more of the patents licensed to that party under this Agreement, or (b) such party is obligated to provide information, support or assistance to a Third
Party pursuant to any compulsory process of any court, administrative or legislative body (and in such event, such party shall provide at least fourteen (14) days prior written notice to the other party such that the other party may file a
motion to quash or take other appropriate action). 
  

 - 5 - 

 5. ROYALTIES 
 5.1 Initial Royalty Payment. As partial consideration for GE’s license under SonoSite’s U.S. Patent No. 5,722,412, GE shall pay SonoSite a non-refundable, non-creditable, initial
royalty payment of Twenty-one Million and No/100 U.S. Dollars ($21,000,000.00) (the “Initial Payment”). GE’s obligation to make the Initial Payment shall be irrevocable, regardless of any patent office actions or court
ruling regarding U.S. Patent No. 5,722,412. GE shall pay such Initial Payment to SonoSite within ten (10) business days of the Effective Date. GE shall make such Initial Payment using a wire transfer to the following bank account:

 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 5.2 Ongoing Royalty Payments. As partial consideration for GE’s license under SonoSite’s U.S. Patent No. 5,722,412, at the point of initial Sale of each Royalty-Based Product during
the Royalty Period, GE shall pay SonoSite ongoing royalties of: 
 For each Royalty-Based Product that is [**] of the [**] of
such Royalty-Based Product; and 
 For each Royalty-Based Product that is [**] of [**] Sales of such Royalty-Based Product.

 If any Royalty-Based Products have been made in the United States prior to the Royalty Period expiration date, but have not been Sold by or
on behalf of GE to Third Parties before the Royalty Period expiration date (“Unsold RBP”), then within [**] during the period from the Royalty Period expiration date until the [**] of such expiration date, GE shall pay
SonoSite the applicable royalty payment set forth in this Section 5.2 for all Unsold RBP Sold on or after the Royalty Period expiration date but before the [**] of the Royalty Period expiration date. No royalty shall be due for Sales of
Royalty-Based Products for which a royalty has already been paid, and no royalty shall be due on Sales of ultrasound system hardware components, accessories or software that constitute less than a complete Royalty-Based Product following the initial
Sale. For the avoidance of doubt, Sales of Royalty-Based Products within GE for resale or transfer to a Third Party shall not be subject to a royalty, provided that such resale or transfer to a Third Party shall be subject to a royalty payment. GE
shall pay SonoSite royalties due on Royalty-Based Product Sales occurring in a [**] within [**] of the end of that [**]. Such royalties shall be due for each [**] that, in whole or in part, falls within the Royalty Period. 
  
  

	**	Confidential Treatment Requested. 

  

 - 6 - 

 Payment shall be made by wire transfer using the account information provided in Section 5.1. Each of
the [**] royalty payments shall be accompanied by a written royalty payment report which sets forth: (a) a list of Royalty-Based Products Sold during that [**]; (b) the total Net Sales for Royalty-Based Products Sold in that [**]; and
(c) the calculated royalty payment amount due hereunder. 
 5.3 Prospective Rights. The parties agree that GE’s Initial Payment
in Section 5.1 and GE’s ongoing royalty payments in Section 5.2 are payments for prospective rights and licenses to SonoSite’s U.S. Patent No. 5,722,412, and are not payments for any releases of GE by SonoSite pursuant to
this Agreement. Any communication by a party with a Third Party, including any communication pursuant to Section 12.3, shall not contradict the terms of this Section 5.3. 
 5.4 Records. During the Royalty Period, GE shall maintain full, true and accurate records pertaining to GE’s royalty payment reports and royalty payments due to SonoSite at a GE facility or as
such records would be kept in the ordinary course of business. GE shall retain such records for a minimum of [**] following the end of the [**] to which they pertain. For a period of [**] after receipt of a royalty payment report and royalty payment
under Section 5.2, SonoSite shall have the right to engage a certified public accountant or accounting firm to inspect such records to verify the accuracy of such royalty payment report and royalty payment. Such inspections will be scheduled
during normal business hours upon at least [**] prior written notice to GE and will be performed at a location mutually agreeable to both parties (but in the absence of mutual agreement, at the location where such records are kept). Following any
inspection under this Section 5.4, the certified public accountant or accounting firm shall deliver a written report to SonoSite and GE, disclosing whether the royalty payment reports submitted by GE are correct or incorrect, whether the
royalty payments paid are correct or incorrect, and in each case, shall provide specific details concerning the amounts of any discrepancies and/or any discrepancies in GE’s record-keeping obligations, but shall not disclose to SonoSite any
other information confidential to GE. GE shall pay any additional royalty payments due to SonoSite within [**] after GE’s receipt of the written inspection report, together with interest on the overdue royalty payments at an annual rate of
[**], assessed from the day payment was initially due. Any excess royalty payments paid by GE to SonoSite shall be credited against future royalty payments owed to SonoSite. SonoSite may exercise its right of inspection no more than [**] during any
[**]; provided, however, that if such inspection finds that GE has underpaid its royalty payment obligations under Section 5.2 by more [**], then SonoSite may exercise its right of inspection [**] during such period; and provided further that,
during the first [**] of this Agreement, SonoSite may exercise its right of inspection [**]. The cost of any inspection shall be borne by SonoSite; provided, however, that if GE’s royalty payment underpayment amount exceeds [**] of the royalty
payments that were to be paid to SonoSite, GE also shall reimburse SonoSite for reasonable out-of-pocket expenses incurred by SonoSite in conducting the audit. 
  
  

	**	Confidential Treatment Requested. 

  

 - 7 - 

 6. DISPUTE RESOLUTION 
 6.1 General Dispute Resolution Process. During the term of this Agreement, GE and SonoSite agree to resolve their future disputes, with the exception
of disputes related to this Agreement, in accordance with the following procedure: First, if either party requests in writing a dispute resolution meeting, authorized representatives from each company shall conduct face-to-face negotiations to
attempt to resolve the dispute. If the company representatives are unable to resolve the dispute within [**] of the date of the initial request for a dispute resolution meeting (the “DR Start Date”), a senior manager from
each company shall conduct face-to-face negotiations to attempt to resolve the dispute, and shall identify and reserve the services of an independent, impartial mediator who will be available in the event that senior management is unable to resolve
the dispute and a demand for non-binding mediation is made. If senior management is unable to resolve the dispute within [**] of the DR Start Date, either party may make a written demand for non-binding mediation within [**] after the date that
senior management fails to resolve the dispute. If such a demand is made, the previously identified mediator shall conduct at least a one-day mediation, which shall commence no later than [**] after the date that senior management fails to resolve
the dispute, or the earliest date of availability for the identified mediator. The parties each shall designate a representative(s) to meet with the mediator in good faith in an effort to resolve the dispute. The specific format for the mediation
shall be left to the discretion of the mediator and the designated party representatives. If the parties are unable to resolve the dispute within [**] after the date that senior management fails to resolve the dispute, then (a) the parties may,
at their sole discretion, agree to resolve such dispute through other informal procedural means, including, without limitation, referral to an independent, neutral third party expert, or arbitration, or (b) either party shall be entitled to
exercise its rights and remedies at law and in equity if the dispute resolution process described in this Section 6.1 fails to resolve the dispute. For clarity, the time period for the process described in this Section 6.1 shall not exceed
[**] after the DR Start Date, unless the parties mutually agree in writing to extend [**]. 
 6.2 Resolution of Agreement-Related
Disputes. In the event of a dispute related to either party’s performance under this Agreement, the parties shall apply an expedited dispute resolution process. Under such expedited dispute resolution process (“Expedited
Process”), the company representatives shall have [**] after the date of the initial request for a meeting to implement an Expedited Process (the “EP Start Date”) to resolve the dispute; if the company
representatives are unable to do so, senior management shall have [**] after the EP Start Date in which to resolve the dispute and to identify and schedule an arbitrator. If senior management is unable to resolve the dispute within [**] after the EP
Start Date, either party may make a written demand for binding arbitration within [**] after the date that senior management fails to resolve the dispute. If such a demand is made, the previously identified arbitrator shall conduct at least a
one-day arbitration pursuant to AAA rules, which shall commence no later than [**] after the date that senior management fails to resolve the dispute, or the earliest date of availability for the identified arbitrator. Any decision of the arbitrator
shall be final. 
  
  

	**	Confidential Treatment Requested. 

  

 - 8 - 

 6.3 [**]. In addition to the dispute resolution process set forth in Section 6.1, during the [**]
following the Effective Date, [**]. 
 7. [**] 
 7.1 In SonoSite’s sole discretion, SonoSite may elect to [**]. For purposes of clarity, nothing in this Agreement or in any other understanding between the parties shall be deemed to waive
SonoSite’s right to assert the doctrine of patent exhaustion with respect to [**]. 
 8. POINT OF
CARE ULTRASOUND FOUNDATION 
 8.1 During the [**] following the Effective Date, GE and SonoSite
each agree to equally contribute up to a total of [**] to a new, independent foundation focused on clinical research, education, training, promotion, market-development, medical advancement, scientific knowledge and effective health care delivery in
the point of care ultrasound market. Any monetary contributions under this Section 8.1 shall be contingent upon the formation of such a foundation through a separate agreement, under terms and conditions acceptable to both parties. GE and
SonoSite shall cooperate in good faith to finalize an agreement that forms such a foundation within [**] of the Effective Date. 
 9.
REPRESENTATIONS & WARRANTIES 
 9.1 Authority. Each party represents and warrants that it has
the corporate power and authority to enter into and to perform its obligations under this Agreement, including without limitation, granting the general releases in Section 3 and the patent licenses and releases in Section 4. 
 9.2 No Assignment of Claims. Each party hereby represents and warrants that it has not assigned or transferred, or purported to assign or transfer,
to any person or entity any Claim, action, right of action, cause of action, liability, obligation or demand released hereunder, and further agrees to indemnify the other party hereto against any liability, loss, damage, cost or expense, including
reasonable attorneys’ fees, arising out of any breach of this representation and warranty. 
 9.3 Disclaimer. EXCEPT AS EXPRESSLY
SET FORTH IN THIS SECTION 9, GE AND SONOSITE MAKE NO WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THIS AGREEMENT, AND SPECIFICALLY DISCLAIM ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR THE
VALIDITY, SCOPE OR ENFORCEABILITY OF THE PATENTS LICENSED IN SECTION 4. 
  
  

	**	Confidential Treatment Requested. 

  

 - 9 - 

 9.4 Limitations. Nothing in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation that anything made, used, sold, offered for sale, imported, or otherwise disposed of pursuant to this Agreement is or will be free from
infringement of patents or other intangible rights of Third Parties; or 

  

	 	(b)	a requirement that SonoSite or GE shall file any patent application, secure any patent, or maintain any patent in force; or 

  

	 	(c)	an obligation that SonoSite or GE bring or prosecute actions or suits against Third Parties for infringement of the Licensed SonoSite Patents or Licensed GE Patents,
respectively; or 

  

	 	(d)	an obligation to furnish any manufacturing or technical information or know-how. 

 10. ASSIGNMENT 
 10.1 Assignment by GE. This Agreement has been
entered into by SonoSite in reliance upon the particular characteristics of GE and is personal to GE. Neither this Agreement, nor any rights or obligations hereunder, may be assigned, pledged or encumbered by GE without the express prior written
approval of SonoSite, which may not be unreasonably withheld or delayed. Any such assignment absent such express prior written approval of SonoSite shall be null and void. Notwithstanding the foregoing, GE may assign this Agreement without
SonoSite’s consent to a successor-in-interest pursuant to a Change of Control if such successor-in-interest agrees to be bound by this Agreement in a writing delivered to SonoSite at the time of or reasonably promptly after such Change of
Control, and such successor-in-interest thereafter shall be “GE” for purposes of this Agreement; provided, however, that the rights, licenses, covenants and obligations set forth in this Agreement which inure to the benefit of such
successor-in-interest shall extend only to the Licensed GE Products. Should any successor fail to materially meet all terms of this Agreement, such failure shall be subject to the Expedited Process described in Section 6.2. Upon any permitted
assignment, this Agreement and all of the rights and obligations of GE under this Agreement shall be binding upon and inure to the benefit of its assignee or successor-in-interest. 
 10.2 Assignment by SonoSite. This Agreement has been entered into by GE in reliance upon the particular characteristics of SonoSite and is personal to SonoSite. Neither this Agreement, nor any
rights or obligations hereunder, may be assigned, pledged or encumbered by SonoSite without the express prior written approval of GE, which may not be unreasonably withheld or delayed. Any such assignment absent such express prior written approval
of GE shall be null and void. Notwithstanding the foregoing, SonoSite may assign this Agreement without GE’s consent to a successor-in-interest pursuant to a Change of Control if such successor-in-interest agrees to be bound by this Agreement
in a writing delivered to GE at the time of or reasonably promptly after such Change of Control, and such successor-in-interest thereafter shall be “SonoSite” for purposes of this Agreement; provided, however, that the rights, licenses,
covenants and obligations set forth in this Agreement which inure to the benefit of such successor-in-interest shall extend only to the Licensed SonoSite Products. Should any successor

  

 - 10 - 

 
fail to materially meet all terms of this Agreement, such failure shall be subject to the Expedited Process described in Section 6.2. Upon any permitted assignment, this Agreement and all of
the rights and obligations of SonoSite under this Agreement shall be binding upon and inure to the benefit of its assignee or successor-in-interest. 
 11. TERM & TERMINATION 
 11.1 Term. The term of this Agreement shall begin on the
Effective Date and shall continue until the expiration of the last-to-expire patent of all the patents licensed in Section 4. 
 11.2
Material Breach. In the event of either party’s or its successor’s material breach of this Agreement, the other party shall provide written notice of the alleged breach (the “Notice of Breach”) to the
breaching party (or its successor). If such material breach relates to any provision of this Agreement other than Section 4.4 and remains uncured for thirty (30) days after receipt by the breaching party (or its successor) of such Notice
of Breach, then the other party shall follow the dispute resolution procedures set forth under Section 6.2. If such material breach relates to Section 4.4 and constitutes the filing of a reissue, re-examination, interference, opposition,
declaratory judgment action or other intentional challenge initiated by the licensee party to the validity or enforceability of licensor party patent(s) for which license rights have been granted under this Agreement, and the breaching party fails
to initiate a cure within (30) days after receipt of the Notice of Breach or fails to complete such cure within ninety (90) days after receipt of the Notice of Breach, the non-breaching party may terminate the license rights granted to the
breaching party under this Agreement. 
 12. MISCELLANEOUS 
 12.1 Governing Law. This Agreement shall be governed by and interpreted in accordance with the internal substantive laws of the State of New York, without regard to or application of choice of law
rules or principles. 
 12.2 Compliance with Laws. Notwithstanding anything contained in this Agreement to the contrary, the obligations
of the parties shall be subject to all laws, present and future, of any government having jurisdiction over the parties and this transaction, and to orders, regulations, directions or requests of any such government. 
 12.3 Confidentiality of Agreement Terms. The parties hereto shall keep the negotiations leading up to and the terms of this Agreement confidential
and shall not divulge such information to any Third Party except: (a) with the prior written consent of the other party; (b) as may be required by any applicable law or legal process, regulation or accounting rules (including, without
limitation, any securities laws), including in confidence to legal advisors in their capacity of advising a party in such matters; (c) in confidence to its legal counsel, accountants, banks and financing sources and their advisors solely in
connection with complying with laws, regulations or rules regarding financial transactions; or (d) pursuant to a non-disclosure agreement with a Third Party seeking to acquire, merge or consolidate with a party where such non-disclosure
agreement restricts access to the information to only those employees of the Third Party with a need to know; provided however, that in (b) and (c) above, the

  

 - 11 - 

 
disclosing party shall use all legitimate and legal means available to minimize the disclosure to Third Parties, including without limitation, seeking a confidential treatment request or
protective order whenever appropriate or available. In addition, in the event this Agreement or its terms are sought through discovery or compulsory process of any court, administrative or legislative body, the disclosing party shall first provide
the non-disclosing party with at least fourteen (14) days prior written notice such that the non-disclosing party may file a motion to quash or take other appropriate action. Notwithstanding the foregoing, the existence of this Agreement (as
distinguished from its terms, which shall remain confidential) is not confidential and may be divulged to Third Parties. 
 12.4 Information
Developed in Connection with the Actions. With the exception of the other party’s confidential information, each party shall retain the right to use and exploit for all purposes any and all documents, information and other work product
pertaining to its own patents, patent applications and patent rights that such party and/or its attorneys developed in connection with the Actions. 
 12.5 Entire Agreement; Headings; Amendments. The terms and conditions of this Agreement constitute the entire agreement between the parties with respect to the subject matter hereof, and merge and supersede all prior and
contemporaneous agreements, understandings, negotiations and discussions with respect to such subject matter. Notwithstanding the foregoing sentence, all protective orders, conflict waiver letters with law firms and other agreements executed by the
parties that are in effect as of the Effective Date shall not be superseded or modified by this Agreement. Neither of the parties shall be bound by any conditions, definitions, warranties, understandings, or representations with respect to the
subject matter hereof other than as expressly provided herein. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. No oral explanation or
oral information by either party hereto shall alter the meaning or interpretation of this Agreement. No amendments or modifications shall be effective unless in writing signed by authorized representatives of both parties. These terms and conditions
will prevail notwithstanding any different, conflicting or additional terms and conditions that may appear on any purchase order, acknowledgment or other writing not expressly incorporated into this Agreement. 
 12.6 Counterparts. This Agreement may be executed by original or facsimile signature in two (2) or more counterparts, all of which, taken
together, shall be regarded as one and the same instrument. 
  

 - 12 - 

 12.7 Notices. All notices required or permitted to be given hereunder shall be in writing, shall make
reference to this Agreement, and shall be delivered personally, or dispatched by prepaid air courier or by registered or certified airmail, postage prepaid, addressed as follows: 
  

			
	 If to GE
	  	 If to SonoSite

	 Postal address:
	  	Postal address:
	 GE Healthcare, RP2131
	  	 SonoSite, Inc.

	 P.O. Box 414
	  	 21919 30th
 Drive SE

	 Milwaukee, WI 53201
	  	 Bothell, WA 98021-3904

		
	 Courier address:
	  	Courier Address:
	 GE Healthcare, RP2131
	  	 SonoSite, Inc.

	 9900 West Innovation Drive
	  	 21919 30th
 Drive SE

	 Wauwatosa, WI 53226
	  	 Bothell, WA 98021-3904

		
	 Attn: Legal Dept., Patent Counsel
	  	Attn: General Counsel
		
	 Fax: [**]
	  	Fax: [**]

 Such notices shall be deemed served when
received by addressee or, if delivery is not accomplished by reason of some act or omission of the addressee, when tendered for delivery. Either party may give written notice of a change of address in accordance with this Section 12.7 and,
after notice of such change has been received by the notified party, any notice or request shall thereafter be given to such notifying party at such changed address. 
 12.8 Relationship of Parties. The parties hereto are independent contractors. Neither party has any express or implied right or authority to assume or create any obligations on behalf of the other
or to bind the other to any contract, agreement or undertaking with any third party other than as expressly set forth herein. Nothing in this Agreement shall be construed to create a partnership, joint venture, employment or agency relationship
between the parties hereto. Neither party shall have authority to waive any applicable privilege or doctrine on behalf of the other party; nor shall any waiver of an applicable privilege of doctrine by the conduct of either party be construed to
apply to the other party. Nothing in this Agreement shall be construed to affect the separate and independent representation of the parties by their respective counsel. 
 12.9 Severability. The terms and conditions stated herein are declared to be severable. If any paragraph, provision, or clause in this Agreement shall be found or be held to be invalid or
unenforceable in any jurisdiction in which this Agreement is being performed, the remainder of this Agreement shall be valid and enforceable and the parties shall use good faith to negotiate a substitute, valid and enforceable provision which most
nearly effects the parties’ intent in entering into this Agreement. 
 12.10 Waiver. Failure by either party to enforce any term of
this Agreement shall not be deemed a waiver of future enforcement of that or any other term in this Agreement. 
  
  

	**	Confidential Treatment Requested. 

  

 - 13 - 

 12.11 Further Acts. Each party hereto shall execute, acknowledge and deliver all such further
instruments, and do all such further acts, as may be necessary or appropriate to carry out the intent and purposes of this Agreement. 
 12.12
Construction; Interpretation. This Agreement shall be construed as if the parties jointly prepared it, and any uncertainty and ambiguity in the Agreement shall not be construed or interpreted against either party individually. The terms
defined in this Agreement and denoting a singular number only shall include the plural and vice versa. 
 12.13 Fees and Costs Incurred in
the Actions. Each party shall bear its own fees and costs, including without limitation, attorneys’ and experts’ fees and costs, incurred in connection with the Actions. 
 12.14 No Admission of Liability. This Agreement sets forth the parties’ compromise of disputed claims and neither the promises exchanged between the parties nor any other statements herein are
to be construed as an admission of any fault, liability, infringement, wrongdoing or culpability whatsoever on the part of any party with respect to any Claim, counterclaim, obligation or liability released, or any other form of admission with
respect to any matter or dispute. The parties expressly deny any such liability, and each party expressly denies allegations of the other party with respect to the Actions. 
 IN WITNESS WHEREOF, each of the parties hereto has caused this Confidential Settlement and License Agreement to be executed by its duly authorized officer or representative as of the Effective Date:

  

							
	Dated: October 16, 2009	 		 	GENERAL ELECTRIC COMPANY
				
		 		 	By:	 	 /S/    S. OMAR
ISHRAK

		 		 		 	S. Omar Ishrak
		 		 		 	CEO – GE Healthcare Systems

  

							
	Dated: October 16, 2009 	 		 	SONOSITE, INC.
				
		 		 	By:	 	 /S/    KEVIN
GOODWIN

		 		 		 	Kevin Goodwin
		 		 		 	President & CEO

  

 - 14 - 

 Exhibit A 
  

							
	         [**]        
	  	         [**]        
	  	         [**]        
	  	         [**]        

				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  	[**]	  	[**]	  	[**]
	  	  	[**]	  	[**]
				
	 [**]
	  		  	[**]	  	[**]
				
	 [**]
	  		  	[**]	  	[**]

  

	**	Confidential Treatment Requested. 

  

 - 1 -EXHIBIT 10.12

 Exhibit 10.12 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS AND
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
  IN ADDITION, THIS WARRANT AND THE
SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF
SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF THREE HUNDRED SIXTY (360) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS OF THE PUBLIC OFFERING OF THE COMPANY’S SECURITIES PURSUANT TO REGISTRATION STATEMENT NO.: 333-164273 AS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(G)(2). 
  TRI-TECH HOLDING
INC. 
 WARRANT 
 __________ Ordinary Shares 
 __________, 2010 
 This WARRANT (this “Warrant”) of Tri-Tech Holding Inc., a company duly organized and validly existing under the laws
of the Cayman Islands (the “Company”), is being issued pursuant to that certain Underwriting Agreement, dated as of
[                    ], 2010, by and between the Company and Newbridge Securities Corp., the representative of the Underwriters (the
“Representative”) relating to a firm commitment public offering (the “Offering”) of _______ ordinary shares, $0.001 par value (the “Ordinary Shares”), of the Company. 
 FOR VALUE RECEIVED, the Company hereby grants to [Insert Underwriter Name] and its permitted successors and assigns (collectively,
the “Holder”) the right to purchase from the Company up to __________________ (                    ) Ordinary Shares (such
Ordinary Shares underlying this Warrant, the “Warrant Shares”), at a per share purchase price equal to $[            ] [145% OF THE PUBLIC OFFERING PRICE] (the
“Exercise Price”), subject to the terms, conditions and adjustments set forth below in this Warrant. 
  1.
Vesting of Warrant. This Warrant shall vest and become exercisable on the Base Date. For purposes of this Warrant, the “Base Date” shall mean
[                    ], 2010. Except as

  
otherwise provided for herein or as permitted by applicable rules of the Financial Industry Regulatory Authority, Inc., (“FINRA”) this Warrant and the Warrant Shares shall not be
sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Warrant or the Warrant Shares, for the 360 days
following the Base Date. The Warrant and the Warrant Shares are subject to a 360-day lock-up pursuant to Section 9 hereof in accordance with FINRA Rule 5110(g)(2). 
  2. Expiration of Warrant. This Warrant shall expire on the five (5) year anniversary of the Base Date (the “Expiration
Date”). 
 3. Exercise of Warrant. This Warrant shall be exercisable pursuant to the terms of this
Section 3. 
 3.1 Manner of Exercise. 
 (a) This Warrant is exercisable in whole or in part at any time and from time to time. Such exercise shall be effectuated by submitting to the Company (either by delivery to the Company or by facsimile
transmission as provided in Section 12 hereof) a completed and duly executed Notice of Exercise (substantially in the form attached to this Warrant) as provided in this paragraph. The date such Notice of Exercise is faxed to the Company shall
be the “Exercise Date,” provided that the Holder of this Warrant tenders this Warrant Certificate to the Company within five (5) business days thereafter. The Notice of Exercise shall be executed by the Holder of this Warrant and
shall indicate the number of Warrant Shares then being purchased pursuant to such exercise. Upon surrender of this Warrant Certificate, together with appropriate payment of the Exercise Price for the Warrant Shares purchased, the Holder shall be
entitled to receive a certificate or certificates for the Ordinary Shares so purchased. The Exercise Price may be paid in a “cashless” or “cash” exercise or a combination thereof pursuant to Section 3.1(b) and/or
Section 3.1(c) below. 
 (b) If the Notice of Exercise form elects a “cashless” exercise, the Holder shall
thereby be entitled to receive a number of Ordinary Shares determined as follows: 
 X = Y [(A – B)/A] 
 where: 
 X = the
number of Warrant Shares to be issued to the Holder. 
 Y = the number of Warrant Shares with respect to which this Warrant is
being exercised. 
 A = the Fair Market Value 
 B = the Exercise Price. 
 For purposes of this Section 3.1(b), “Fair
Market Value” shall be the closing price of the Ordinary Shares as reported by the Nasdaq Capital Market, or if quoted on an automated

  

 2 

 
quotation service, such automated quotation service, on the date immediately prior to the Exercise Date. If the Ordinary Shares are not then listed on a national stock exchange or such other
quotation system or association, the Fair Market Value of one Ordinary Share as of the date of determination, shall be as determined in good faith by the Board of Directors of the Company and the Holder. If the Ordinary Shares are not then listed on
a national securities exchange or such other quotation system or association, the Board of Directors of the Company shall respond promptly, in writing, to an inquiry by the Holder prior to the exercise hereunder as to the fair market value of an
Ordinary Share as determined by the Board of Directors of the Company. In the event that the Board of Directors of the Company and the Holder are unable to agree upon the fair market value, the Company and the Holder shall jointly select an
appraiser, who is experienced in such matters. The decision of such appraiser shall be final and conclusive, and the cost of such appraiser shall be borne equally by the Company and the Holder. Such adjustment shall be made successively whenever
such a payment date is fixed. 
 (c) If the Notice of Exercise form elects a “cash” exercise, the Exercise Price per
Ordinary Share for the shares then being exercised shall be payable in cash or by certified or official bank check. 
 3.2
When Exercise Effective. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the Business Day on which this Warrant shall have been duly surrendered to the Company as provided in
Sections 3.1 and 12 hereof, and, at such time, the Holder in whose name any certificate or certificates for Warrant Shares shall be issuable upon exercise as provided in Section 3.3 hereof shall be deemed to have become the holder or holders of
record thereof of the number of Warrant Shares purchased upon exercise of this Warrant. 
 3.3 Delivery of Ordinary Share
Certificates and New Warrant. As soon as reasonably practicable after each exercise of this Warrant, in whole or in part, and in any event within three (3) Business Days thereafter, the Company, at its expense (including the payment by it
of any applicable issue taxes), will cause the name of the Holder (or as Holder may direct) to be entered in the register of members in respect of the Warrant Shares and further cause to be issued in the name of and delivered to the Holder hereof
or, subject to Sections 9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct: 
 (a) a certificate or certificates for the number of duly authorized, validly issued, fully paid and nonassessable Warrant Shares to which the Holder shall be entitled upon exercise; and 
 (b) in case exercise is in part only, a new Warrant document of like tenor, dated the date hereof, for the remaining number of Warrant Shares
issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant (including the delivery of any Warrant Shares as payment of the Exercise Price for such partial exercise of this Warrant). 
 4. Certain Adjustments. For so long as this Warrant is outstanding: 
  

 3 

 4.1 Mergers or Consolidations. If at any time after the date hereof there shall be a
capital reorganization (other than a combination or subdivision of the Ordinary Shares otherwise provided for herein) resulting in a reclassification to or change in the terms of securities issuable upon exercise of this Warrant (a
“Reorganization”), or a merger or consolidation of the Company with another corporation, association, partnership, organization, business, individual, government or political subdivision thereof or a governmental agency (a
“Person” or the “Persons”) (other than a merger with another Person in which the Company is a continuing corporation and which does not result in any reclassification or change in the terms of securities issuable
upon exercise of this Warrant or a merger effected exclusively for the purpose of changing the domicile of the Company) (a “Merger”), then, as a part of such Reorganization or Merger, lawful provision and adjustment shall be made so
that the Holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of stock or any other equity or debt securities or property receivable upon such Reorganization or Merger by a holder of the number of
Ordinary Shares which might have been purchased upon exercise of this Warrant immediately prior to such Reorganization or Merger. In any such case, appropriate adjustment shall be made in the application of the provisions of this Warrant with
respect to the rights and interests of the Holder after the Reorganization or Merger to the end that the provisions of this Warrant (including adjustment of the Exercise Price then in effect and the number of Warrant Shares) shall be applicable
after that event, as near as reasonably may be, in relation to any shares of stock, securities, property or other assets thereafter deliverable upon exercise of this Warrant. The provisions of this Section 4.1 shall similarly apply to
successive Reorganizations and/or Mergers. 
 4.2 Splits and Subdivisions; Dividends. In the event the Company should at
any time or from time to time effectuate a split or subdivision of the outstanding Ordinary Shares or pay a dividend in or make a distribution payable in additional Ordinary Shares or other securities or rights convertible into, or entitling the
holder thereof to receive, directly or indirectly, additional Ordinary Shares (hereinafter referred to as the “Ordinary Share Equivalents”) without payment of any consideration by such holder for the additional Ordinary Shares or
Ordinary Shares Equivalents (including the additional Ordinary Shares issuable upon conversion or exercise thereof), then, as of the applicable record date (or the date of such distribution, split or subdivision if no record date is fixed), the per
share Exercise Price shall be appropriately decreased and the number of Warrant Shares shall be appropriately increased in proportion to such increase (or potential increase) of outstanding shares; provided, however, that no adjustment shall be made
in the event the split, subdivision, dividend or distribution is not effectuated. 
 4.3 Combination of Shares. If the
number of Ordinary Shares outstanding at any time after the date hereof is decreased by a combination of the outstanding Ordinary Shares, the per share Exercise Price shall be appropriately increased and the number of shares of Warrant Shares shall
be appropriately decreased in proportion to such decrease in outstanding shares. 
 4.4 Adjustments for Other
Distributions. In the event the Company shall declare a distribution payable in securities of other Persons, evidences of indebtedness issued by the Company or other Persons, assets (excluding cash dividends or distributions to the holders of
Ordinary Shares paid out of current or retained earnings and declared by the Company’s board of

  

 4 

 
directors) or options or rights not referred to in Sections 4.1, 4.2 or 4.3, then, in each such case for the purpose of this Section 4.4, upon exercise of this Warrant, the Holder shall be
entitled to a proportionate share of any such distribution as though the Holder was the actual record holder of the number of Warrant Shares as of the record date fixed for the determination of the holders of Ordinary Shares of the Company entitled
to receive such distribution. 
 5. No Impairment. The Company will not, by amendment of its memorandum and articles of
association or through any consolidation, merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all of the terms and in the taking of all actions necessary or appropriate in order to protect the rights of the Holder against impairment. 
 6. Chief Financial Officer’s Report as to Adjustments. With respect to each adjustment pursuant to Section 4 of this
Warrant, the Company, at its expense, will promptly compute the adjustment or re-adjustment in accordance with the terms of this Warrant and cause its Chief Financial Officer to certify the computation (other than any computation of the fair value
of property of the Company, as the case may be) and prepare a report setting forth, in reasonable detail, the event requiring the adjustment or re-adjustment and the amount of such adjustment or re-adjustment, the method of calculation thereof and
the facts upon which the adjustment or re-adjustment is based, and the Exercise Price and the number of Warrant Shares or other securities purchasable hereunder after giving effect to such adjustment or re-adjustment, which report shall be mailed by
first class mail, postage prepaid to the Holder. The Company will also keep copies of all reports at its office maintained pursuant to Section 10.2(a) hereof and will cause them to be available for inspection at the office during normal
business hours upon reasonable notice by the Holder or any prospective purchaser of the Warrant designated by the Holder thereof. 
 7. Reservation of Shares. The Company shall, solely for the purpose of effecting the exercise of this Warrant, at all times during the term of this Warrant, reserve and keep available out of its authorized Ordinary Shares, free from
all taxes, liens and charges with respect to the issue thereof and not subject to preemptive rights or other similar rights of shareholders of the Company, such number of its Ordinary Shares as shall from time to time be sufficient to effect in full
the exercise of this Warrant. If at any time the number of authorized but unissued Ordinary Shares shall not be sufficient to effect in full the exercise of this Warrant, in addition to such other remedies as shall be available to Holder, the
Company will promptly take such corporate action as may, in the opinion of its counsel, be necessary to increase the number of authorized but unissued Ordinary Shares to such number of shares as shall be sufficient for such purposes, including
without limitation, using its best efforts to obtain the requisite shareholder approval necessary to increase the number of authorized Ordinary Shares. The Company hereby represents and warrants that all Ordinary Shares issuable upon exercise of
this Warrant shall be duly authorized and, when issued and paid for upon exercise, shall be validly issued, fully paid and nonassessable. 
 8. Listing. The Company shall secure the listing of the Ordinary Shares underlying this Warrant upon each national securities exchange or automated quotation system upon which

  

 5 

 
Ordinary Shares are then listed (subject to official notice of issuance) and shall maintain such listing of Ordinary Shares. The Company shall at all times comply in all material respects with
the Company’s reporting, filing and other obligations under the by-laws or rules of the Nasdaq Capital Market (or such other national securities exchange or market on which the Ordinary Shares may then be listed, as applicable). 
 9. Restrictions on Transfer. During the first twelve (12) months following the Base Date, this Warrant shall not be transferred,
sold, assigned, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in its effective economic disposition by Holder except (i) to officers, directors, employees and/or partners
of the Representative and members of the underwriting syndicate; (ii) by will, or (iii) by operation of law. Notwithstanding any other provisions of this Section 9, this Warrant or the Warrant Shares may only be transferred or
assigned to the persons permitted under FINRA 
 Rule 5110(g)(2) for the 360 days following the Base Date. 
 10. Ownership, Transfer and Substitution of Warrant. 
 10.1 Ownership of Warrant. The Company may treat any Person in whose name this Warrant is registered in the Warrant Register maintained pursuant to Section 10.2(b) hereof as the owner and
holder thereof for all purposes, notwithstanding any notice to the contrary, except that, if and when any Warrant is properly assigned in blank, the Company may (but shall not be obligated to) treat the bearer thereof as the owner of such Warrant
for all purposes, notwithstanding any notice to the contrary. Subject to Sections 9 and 10 hereof, this Warrant, if properly assigned, may be exercised by a new holder without a new Warrant first having been issued. 
 10.2 Office; Exchange of Warrant. 
 (a) The Company will maintain its principal office at the location identified in the prospectus relating to the Offering or at such other offices as set forth in the Company’s most current filing (as
of the date notice is to be given) under the Exchange Act or as the Company otherwise notifies the Holder. 
 (b) The Company
shall cause to be kept at its office maintained pursuant to Section 10.2(a) hereof a Warrant Register for the registration and transfer of the Warrant. The name and address of the holder of the Warrant, the transfers thereof and the name and
address of the transferee of the Warrant shall be registered in such Warrant Register. The Person in whose name the Warrant shall be so registered shall be deemed and treated as the owner and holder thereof for all purposes of this Warrant, and the
Company shall not be affected by any notice or knowledge to the contrary. 
 (c) Upon the surrender of this Warrant, properly
endorsed, for registration of transfer or for exchange at the office of the Company maintained pursuant to Section 10.2(a) hereof, the Company at its expense will (subject to compliance with Section 9 hereof, if applicable) execute and
deliver to or upon the order of the Holder thereof a new Warrant of like tenor, in the name of such holder or as such holder (upon payment by such holder of any

  

 6 

 
applicable transfer taxes) may direct, calling in the aggregate on the face thereof for the number of Ordinary Shares called for on the face of the Warrant so surrendered (after giving effect to
any previous adjustment(s) to the number of Warrant Shares). 
 10.3 Replacement of Warrant. Upon receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, upon delivery of indemnity reasonably satisfactory to the Company in form
and amount or, in the case of any mutilation, upon surrender of this Warrant for cancellation at the office of the Company maintained pursuant to Section 10.2(a) hereof, the Company, at its expense, will execute and deliver, in lieu thereof, a
new Warrant of like tenor and dated the date hereof. 
 11. No Rights or Liabilities as Stockholder. No Holder shall be
entitled to vote or receive dividends or be deemed the holder of any Ordinary Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to
confer upon the Holder, as such, any of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any
corporate action (whether upon any recapitalization, issuance of shares, reclassification of shares, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription
rights or otherwise until the Warrant shall have been exercised and the Ordinary Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. The Holder will not be entitled to share in the assets of the Company in
the event of a liquidation, dissolution or the winding up of the Company. 
 12. Notices. Any notice or other
communication in connection with this Warrant shall be given in writing and directed to the parties hereto as follows: (a) if to the Holder, c/o [Insert address]; or (b) if to the Company, to the attention of its Chief Executive Officer at
its office maintained pursuant to Section 10.2(a) hereof; provided, that the exercise of the Warrant shall also be effected in the manner provided in Section 3 hereof. Notices shall be deemed properly delivered and received when
delivered to the notice party (i) if personally delivered, upon receipt or refusal to accept delivery, (ii) if sent via facsimile, upon mechanical confirmation of successful transmission thereof generated by the sending telecopy machine,
(iii) if sent by a commercial overnight courier for delivery on the next Business Day, on the first Business Day after deposit with such courier service, or (iv) if sent by registered or certified mail, five (5) Business Days after
deposit thereof in the U.S. mail. 
 13. Payment of Taxes. The Company will pay all documentary stamp taxes attributable
to the issuance of Ordinary Shares underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the transfer or
registration of this Warrant or any certificate for Ordinary Shares underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Ordinary Shares underlying this Warrant upon exercise hereof. 
  

 7 

  14. Miscellaneous. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought. This Warrant shall be construed and enforced in accordance with and governed by the
laws of the State of Delaware. The section headings in this Warrant are for purposes of convenience only and shall not constitute a part hereof. 
  [Signature Page Follows] 
  

 8 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the
date first above written. 
  

			
	TRI-TECH HOLDING INC.
		
	By:	 	 
		 	Name:
		 	Title:

 [Signature Page to
Representative’s Warrant] 
  

 9 

 EXHIBIT A 
 FORM OF EXERCISE NOTICE 
 [To be executed only upon exercise of Warrant]

 To Tri-Tech Holding Inc.: 
 The undersigned registered holder of the within Warrant hereby irrevocably exercises the Warrant pursuant to Section 3.1 of the Warrant with respect to __________ Warrant Shares, at an exercise price per share of
$            , and requests that the certificates for such Warrant Shares be issued, subject to Sections 9 and 10, in the name of, and delivered to: 
  
  
  
  
  
  
  
  
 The undersigned is hereby making payment for the Warrant Shares in the following manner: _______________________ [describe desired payment
method as provided for in 3.1 of the Warrant]. 
 The undersigned hereby represents and warrants that it is, and has been since
its acquisition of the Warrant, the record and beneficial owner of the Warrant. 
 Dated: _______________ 
  
  
 Print or Type Name 
  
  
 (Signature
must conform in all respects to name of holder as specified on the face of Warrant) 
  
  
 (Street
Address) 
  
  
 (City)                (State)                (Zip Code) 

 EXHIBIT B 
 FORM OF ASSIGNMENT 
 [To be executed only upon transfer of Warrant]

 For value received, the undersigned registered holder of the within Warrant hereby sells, assigns and transfers unto
_____________________ [include name and addresses] the rights represented by the Warrant to purchase __________ Ordinary Shares of Tri-Tech Holding Inc. to which the Warrant relates, and appoints _____________________ Attorney to make such transfer
on the books of Tri-Tech Holding Inc. maintained for the purpose, with full power of substitution in the premises. 
  

							
		 	Dated:	 		 	 
		 		 		 	(Signature must conform in all respects
to name of holder as specified on the
face of Warrant)
				
		 		 		 	 
		 		 		 	(Street Address)
				
		 		 		 	 
		 		 		 	(City)                (State)                (Zip Code)
			
		 	Signed in the presence of:	 	 
		 		 		 	(Signature of Transferee)
				
		 		 		 	 
		 		 		 	(Street Address)
				
		 		 		 	 
		 		 		 	(City)                (State)                (Zip Code)
		 	Signed in the presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]